Rosanna Fiallo-Scharer, MD
Associate Professor, Medical College of Wisconsin
Program Director, Diabetes, Children's Hospital of Wisconsin
Member, Children's Specialty Group
Children's Hospital of Wisconsin - Main Campus
9000 W Wisconsin Avenue
Milwaukee, WI 53226
Office: (414) 266-6750
MD: Universidad Nacional Pedro Henriquez Urena Escuela de Medicina, 1983-1989
Residency: Monmouth Med Center (Long Beach, NJ), Pediatrics, 1992-1995
Fellowship: New York and Presbyterian Hospitals - Cornell Campus, Pediatric Endocrinology, 1995-1998
Board Certifications: American Board of Pediatrics-Certified-Pediatric Endocrinology
Diabetes, adrenal disorders and disorders of sexual differentiation
The overall goal of my research is to improve the health and overall quality of life of those living with type 1 diabetes by identifying specific barriers to diabetes self-management in 6 distinct areas of self-care and tailoring interventions to each patient’s self- identified barriers.
Over the past 12 years I have been involved in collaborative research aimed at identifying genes and environmental factors involved in the determination of type 1 diabetes susceptibility and studying the applications of new technologies to improve clinical outcomes and quality of life in patients living with type 1 diabetes. During my almost 11 year appointment at the Barbara Davis Center for Diabetes and the University of Colorado Denver, I collaborated along with Dr. H Peter Chase with other diabetes researchers in academic centers across the country in conducting the first pediatric studies of Continuous Glucose Monitoring (CGM) technology applications in the pediatric population. My participation in the NIH-funded Diabetes Research in Children Network (DirecNet) consortium and the JDRF-funded Artificial Pancreas Project resulted in numerous publications including the first rigorously designed randomized controlled trial of CGM efficacy across a wide age spectrum (Continuous Glucose Monitoring and Intensive Treatment of Type 1 Diabetes. N Engl J Med 359;14 October 2, 2008). The study was powered to independently assess efficacy of CGM use for diabetes management in 3 distinct age groups: young children (8-14), adolescents and young adults (15-24) and older adults (>25). The study had a great impact in disseminating CGM use in clinical practices by facilitating insurance coverage of the technology.
Since I joined the faculty at MCW in November of 2012, I have been involved with the TrialNet Natural History study and the Type 1 diabetes exchange registry. The T1D exchange registry is maintaining a database of information obtained from a consortium of 67 clinical diabetes centers across the US. The rich dataset of the registry provides an opportunity to address numerous issues of relevance to clinicians and patients, including assessments of associations between patient characteristics and diabetes management factors with outcomes. Data recently published by the registry shows that less than 50% of patients of all ages are meeting the recommended goals for HbA1c and other parameters known to prevent long term complications. This highlights an urgent need to modify the chronic health care model in order to promote improved self-management. My main research focus for the next 3 years will be in a collaboration with researchers at UW Madison to implement a patient-centered approach to assigning diabetes management resources based on unique patient needs. This study is sponsored by a $2.1 million grant from the Patient Centered Outcomes Research Institute (PCORI).